As per the agreement, the US rights to the Resolor trademark will be transferred to Shire.
Resolor is approved for use in 33 countries for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.
The drug is currently available in Germany, Ireland, Belgium, France, Greece and the UK, and will be commercially available in Italy in January 2012.
Additional launches throughout Europe are planned for 2012, the company said.
Shire global GI business senior vice president Roger Adsett said they look forward to define the path forward for registration of medicine as treatment for chronic constipation in the US.